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Abstract
The dopamine receptor subtypes known as DI and D2 have been shown to fonn a heteromer
complex, which is thought to lead to the disruption of a multitude of signaling pathways within
the brain. As a result, this has been proposed to lead to diseased states such as Alzheimer's and
depression. In previous studies, it has been shown that the use of synthetic peptides corresponding
to the surface interface of the interactions (specifically in the third intracellular loop of D2
interface) within the complex have served to compete against the formation of the heteromer.
Through in vitro biochemical techniques such as SOS-Page and Western blotting, we observed the
degree of dissociation of the Dl-D2 complex through a variety of small peptides. These peptides
consist of peptide 1, 2, 3 and 4 with the sequences corresponding to Ac-EAARRAQE, Ac
EERRAQ, Ac-ARRA, and Ac-AARRAQ, respectively. Peptide 1 was found to be the most
effective in preventing complex formation.
Introduction
Depression is a debilitating illness affecting millions with a prevalence of about 4%
globally. Individuals suffering depression, especially in major depressive episodes, experience
irritability, abnormal sleeping patterns, change in appetite, loss of interest, feelings of guilt or
worthlessness, and lower ability for concentration in day to day activities Intervention today
consists of using antidepressants known as SSRI's (selective serotonin reuptake inhibitors) and
agonists to mimic neurotransmitters involved in mood and energy such as norepinephrine.
However, the effectiveness of these treatments are temporary fixes and not all symptoms can be
abolished. There are also side effects involved with taking these drugs. These side effects include
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nausea. increased appetite, insomnia. blurred vision and fatigue (1, 2).0ne possible explanation
could be the deregulation of the dopaminergic system.
The dopaminergic system is involved in locomotion, behavior, learning, and even emotion.
The disruption of the dopamine receptor structure that regulates this system leads to disease states
such as depression, Alzheimer's, ADHD, drug addiction, and other neuropsychiatric disorders.
The dopamine receptors are G-protein coupled receptors (GPCR) {1,2). There are currently five
subtypes known with reported subclasses (2,3). Among them are the two dopamine receptors DI
and D2. These receptors, through synergistic interaction, regulate cAMP production. cAMP acts
as a crucial secondary messenger (by increasing calcium influx, activating kinase cascades) for
many signaling pathways, allowing the rapid action of neurotransmitters, synaptic transmission,
as well as neuronal gene expression and differentiation (1,2,3). Generally, the pathway of the
expression of D l-D2 leads to the activation CaMKII (calcium calmodulin kinase II a), resulting
in an increase of brain derived neurotrophic factor (BDNF) and allowing for the branching of
dendrites and an increase in neuroplasticity (6,7). It has been thought that the expression of D 1
and 02 in the mesocorticolimbic system may lead to abnormal brain physiology (7). When D1 and
D2 are co-activated as a result of constant drug exposure, it causes a surge in dopamine, increasing
calcium levels in the cell via cAMP. In the long term, this has been show to upregulate the
activation of the transducer Gi, leading to decreased cAMP and decreasing the cell's sensitivity to
dopamine (2). Below in Figure 1 is the mechanism of the different cellular cascades that may
result after D1-D2 stimulation, through the use of different transducers.
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D1 -D�

Figure I : "Dopamine Receptor Complexes Trigger Different Cellular Cascades:
Stimulation of the Dl-D2 receptor complex (on right) spurs a burst of calcium within the cell
activating the neuron, making the cell more prone to firing again, and ultimately forging new
neural connections. Stimulation of the two other complexes influences slower acting biological
cascades involving cyclic AMP (cAMP)." (11)

In striatal neurons, DI and D2 play a significant role in motor behavior and the reward
system. The synergistic stimulation of the receptors has been shown to be responsible for GABA
release and sensitization to drugs such as cocaine (3). This is most likely caused by the activation
of the transducer Gq. The effects of D1 and D2 can be intensified by the use of agonists for both
receptors. In one study, a high affinity agonist drug known as SKF89359 increased Gq and cAMP
levels leading to synaptic plasticity observed by mice development (5).
5

The uniqueness of these two receptors is that they complex to form a heterodimer, unlike
the other classes that exist as monomers. This complexing occurs non-covalently and it is
hypothesized that amino acid residues arginine and glutamate, allowing the stable formation of the
complex. Specifically, it has been found that the third intercellular loop of D2 and the glutamic
acid residues, including the C-terminal tail of D1, tend to have the strongest interactions in the
complex (7).

Undoubtedly, D1-D2 form a heteromer complex as observed after

coimmunopercipitation in rat striatum in vivo (4,7). The effects of DI and D2 have been observed
to be inhibited due to heterooligomeric complexing. The complex was shown to be a target of
antipsychotic drugs administered to schizophrenic patients. The use of clozapine, an anti
psychotic, was shown to significantly uncouple Dl-D2 heteromers.
Dl-D2 is shown to change its affinity states in dopamine regulation. The administration of
stimulants such as amphetamine, was proven to enhance the presence ofD1-D2 as observed in rat
striatum via fluorescence resonance energy transfer FRET (7). In postmortem striatum of
depression patients, the use of a small peptide from rats was able to disrupt D1-D2 heteromers in
pyramidal neurons, but not in the hippocampus. This may indicate that the complex formation of
Dl-D2 may vary in its interactions throughout the brain (7).
Biochemical analyses confirm the presence of the Dl-D2 heteromer complex in
postmortem brains of patients suffering from depression. It was shown that the use of a small
peptide was able to disrupt the complex by observation of decreased escape failures in learned
helplessness tests in rats. Locomotive ability of the rats was not disrupted after administration,
making a small peptide a possible alternative to other medical interventions for depression (8).
In a recent study, a peptide 15 amino acids long was derived from the third intracellular
loop of D2. This peptide was administered intranasally to rats and showed significant ability to
6

decrease learned helplessness (LH), an indicator of depression. The peptide was successful in
uncoupling the complex within the prefrontal cortex as seen by immunoprecipitation (9).
Many of the targets of these small proteins is the surface interface, intracellular loops,
amino/carboxyl terminals, and the transmembrane domains between DI and D2. It has been found
that the carboxyl tail residues of the D 1 receptor Glu404 and Glu405, were critical in the
noncovalent binding with D2 as shown by BRET analysis (4).
In one study, a small interfering peptide of29 amino acids in the third intracellular loop of
the D2 long receptor form was shown to be effective in preventing heteromer formation (10).
D2 Third Loop

Dt carboxyl Tail
1M7

TMS

TM8

CJ!CIIJ
CC(12)

Fig 2: Shows the primary amino acid sequence of the third intracellular loop ofD2 and the
carboxyl tail ofDl. The shaded amino acids represent the inserted 29 amino acid peptide. (10)
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In our lab, we plan to synthesize small peptides in order to observe their effectivity in
disrupting the Dl-D2 heteromer. The four peptides (peptide 1,2,3, and 4) will have the amino acid
sequences EAARRAQE, EERRAQ, ARRA, and AARRAQ, respectively and will be acetylated at
the N-terminus and carboxamides at the C-terminus to effectively cap them. The peptides'
efficiency in the disruption of the complex will be observed through Western Blotting,
conventional dot blots, SOS-page, cross-linking, and gel-electrophoresis assays. The discovery of
a peptide that may inhibit complex formation in low concentrations can be developed into new
pharmaceuticals that may be able to treat depression long-term.
Research Obiectives:
l) To determine what regions of the Dl-D2 complex are most important for sustaining
stability of its formation
2) To synthesize a small synthetic peptide that may be effective in disrupting the Dl-D2
interaction
3) To observe the effectivity of said peptide in uncoupling the Dl-D2 heteromer

Materials and Methods

Peptide Synthesis
Peptide synthesis was carried out using a PS3 Automated Peptide Synthesizer from Protein
Technologies.

The

protecting

groups

used

for

the

ammo

acids

was

N-a

fluorenyltmethylxycarbonyl (FMOC), on a rink amide resin p-methylbenzhydcylamine (MBHA)
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(0.64 mmole/g) on a 0.1 mmole scale. To deprotect the amino-terminus from the FMOC, 20%
piperidine in N,N-dimethylformamide (DMF) was used. After the addition of O-(Benzotriazol
l yl)-1, 1, 3, 3-tetramethyluronium hexafluorophosphate (HBTU), the amino acid was activated
using 0.4 M N,N-diisopropylethylamine (DIEA). The simultaneous deprotection and cleavage of
the peptide from the resin was done by treating the resin with 11 mL 90% trifluororacetic acid
(TFA)/10% scavenger cocktail (phenol, water, and triisopropylsilane). The reaction was allowed
to warm to room temperature, after starting the reaction at 0°C. Uncharged resin was separated and
the peptide was allowed to precipitate out with the use of cold diethyl ether. The precipitate was
then redissolved in a solution of 70%/30% acetonitrile/water. The peptide was then purified using
reverse-phase high performance liquid chromatography (RP-HPLC) on a Jupiter CI8 column (2.2
x 25.0 cm, with flow rate of IO mUmin).A gradient of acetonitirile was employed as follows from
10% acetonitrile (0.1% TFA)/water to 50% acetonitrile (0.1% TFA)/water (0.1% TFA). The
sample was then lyophilized.

Peptide Analysis
Purity of the peptides was assessed using RP-HPLC. The peaks were observed at 220 run,
and purity was determined by peak integration. Electrospray mass spectrometry was used to check
the molecular weights of the peptides.
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D2 and DJ protein synthesis via in vitro translation
Both plasmids, human dopamine receptor l(DRDl - HaloTag® human ORF in pFN2I A)
and human dopamine receptor 2 (DRD2 - HaloTag® human ORF in pFN2IA) from Promega,
were transformed into DH5a E.coli.
Once transformed, DNA was purified from 5ml cultures by the use of PureLink® Quick
Plasmid Miniprep Kit from Invitrogen. Using an alkaline solution and sodium dodecyl sulfate
(SOS), the cells containing the plasmids were lysed. The lysate was then transferred to a silica
membrane selective for the DNA and contaminates were removed using a wash. Tris/EDTA (TE)
buffer was used to elute out the DNA. The DNA was then stored at -20 °C.
The human DI and D2 receptor genes encoded on the plasmids are held on the pFN21A HaloTag®
CMV Flexi® Vector. This vector permits constitutive protein expression on mammalian cells by
use of human cytomegalovirus (CMV). The vector HaloTag® RNA polymerase promoter
sequence is displayed below in Figures 3 and 4 below.
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T7 RNA polymerase
promoter

Ned

Sgfl
Pw1

I C ATGt1. GAAATC GGT ACT ••• GAG GAT CTG TAC m CAG ,W,C GAT AAC �G ATC
HaloTag8 N terminus

JB85bp

�lEV protease recognition

I Nc:o1

JeeATGJ.. 3"

sequence

Figure 3: pFN21A HaloTag CMV Flcxi Vector sequence upstream and downstream of the HaloTag
gene (Promegacom).
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I. Bmtl

pFN21A HaloTa� CMV
FIBI.. Vector
(S064bp)

Pmel

TEVSlte
Sgfl, Pvul
Ncol

Figure 4: pFN21A HaloTag CMV Flcxi Vector circle map and sequence (Promega.com).

For transcription and translation of the system of our gene of interest downstream of T7, a
TnT® Quick Coupled Transcription/franslation System from Promega was used. A 40 µL aliquot
of TnT® Quick Master Mix was added to 0.2-2.0µg of the template circular plasmid DNA with
the addition of 7 µL of nucleus-free water. The reaction was allowed to run 60-90 minutes at a
30°C for protein expression. The TnT® Quick Master Mix couples transcription and translation
due to the system having RNA polymerase, various salts and nucleotides, and Recombinant
RNasin® Ribonuclease Inhibitor (to prevent nonselective protein expression). After incubation,
the mixture was thawed at room temperature then stored in ice. This was done for DI and D2
receptor separately A summary of the TnT® Quick Coupled Transcription/franslation System
from Promega can be found below.
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Figure 5: Summary of the TnT® Quick Coupled Transcriptionffranslation System
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Zoomer © Dot Blot

Filter cubes were pushed into each compartment below each well to form a small porous
opening. Various concentrations of proteins were added to each well including the DI and D2
receptor.
For in vitro analysis of the effectivity of each synthetic peptide in uncoupling the Dl-D2
heteromer, a Zoomer dot blot was conducted. Each of the receptor proteins were diluted to 100
µg/mL and centrifuged. DI and D2 receptors were purchased from Abeam (ab90834 for DI and
abl 12281 for D2) and were made using the the TnT® Quick Coupled Transcription!franslation
System from Promega. The D1 receptor was diluted to 100 µg/mL in 30 µL PBS after thawing. 5
µl of D1 receptor with the PBS solution was added to each well and each well was then blocked
with 50 µL blocking buffer of 10% BSA in PBST (Phosphate Buffered Saline with 20% Tween)
to prevent non-specific binding. 1x PBS was made by using Sg NaCl, 0.2 gKCl, The 1% BSA was
made by dissolving 5g of BSA and 2.5 ml of 20% Triton-X-100 and 487.5 ml of distilled water.
The 10% BSA solution was done diluting 50g of BSA with 2.5 ml ofTriton-X-100 and 487.5 ml
of distilled water. They were then rinsed 4x with 50 µL rinsing buffer of 1% BSA in PBST. 5 µl
of D2 was then added to each well.
Peptides were first diluted by dissolving 0.0010 g in 1ml solution of 100 µl DMS0+900 µl
PBS. This was then diluted 10-fold using PBS. The stock concentration (µM) was then determined
by multiplying the molecular weight of the peptide to the protein dilution. This concentration was
then used to determine the µ1 of protein of the IO fold diluted stock per well needed. This was by
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multiplying the needed µM of protein by the total solution in each well (µl) and setting this equal
to the stock concentration.
The wells were then allowed to incubate for 2 hours or overnight to allow heteromer
complexing. After incubation, 2 µl primary antibody for D2 was added to each well and allowed
to incubate for 5 minutes. The wells were then washed once with 50uL rinsing buffer of I % BSA
in PBST. Secondary D2 antibody was then added for visualization, and the wells were allowed to
incubate for five minutes. The samples were then washed four times with 50 µl rinsing buffer of
1% BSA in PBST.
For all 8 wells, 10µ1 of Clarity™ Western ECL mix was added to each well. This was done
by mixing 50 µI of peroxide solution and 50 µl ofluminol enhancer. The wells were then allowed
to sit for I O minutes and were then imaged. A summary of the reagents and appropriate volumes
can be found below in Table I for Peptide 1. Figure 6 shows a summary of the zoom dot blot
protocol.
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Table 1 : Solution scheme for each well 1 through 8

Sample 1 I Sample 2· sampl03
;
I Peptide

. concentration
I

l Dilute

OµM

10 µ.M

,

' S JLM

I
I
I

I

Sample
15 p.M

I
I

0 µ1

2.5 µ1

1.0

4 µ1

41 Sample 5

- J 25 µM

1 20 µ.M
I
I

!

1 5 µL

Sample 7 Sample 8

Sample 6

-

30 µ.M

-

35 µ.M

___L
-l--

... 6 µL -- 7.5 µL

,9

peptide
I

volume

5 µl

5 µl

Expressed D2 5 µl

5 µl

5 µl

5 µL

5 µL

' 16 µ1

15 µ1

I

I

--

5 µl

-

5 µ1

-

5 µl

t

I
I

Expressd Dl 5 µL

S µL

I

I

' 5 µL

I

in PBS (100
ug/mL)
I

Cold

PBS 20 µ1

buffer

(pH

7.6)
Total Volume 30 µ1

S µL

..

5 µL

·--5 µ1

I
j

I

17.5 µ1
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l____
I

30 µL

l

I

I
'

__

30 µ1

-1 30µ1

_....._

I
I

16

- 30µ1

-·
I

I

- -12.5 µ1

14 µ1

OµL
1- J
L

--

I
I

I

30

µL

--

1 1 µ1

-

30
1

µL

Spot 1 µI antigen.
30 mln

Add SO µI bloddng
buffer, 30 min

Add 1 µI primary
anubody, s min

Add SO µI rinsing
buffer

Add 1 µI labeled
secondary anUbody,
S mln

Add 50 µI rinsing
buffer, 4 times

Detect ---------Fluoresa!nt label

Enzyme Label

Add 10 µI ECI. substme

https://www.vitrozm.com/pages/zoom-blot-fast-and-casy-96-well-dot-blot

Figure 6: Summary of the Zoom Dot Blot Protocol

Western Blotting Co-immunopercipitation
This procedure serves as another quantitative method in observing the effectivity of the
synthetic peptides disrupting the formation ofthe Dl-D2 heteromer. Sample preparation was
prepared in 8 cuvettes. The sample preparation scheme is shown below in Table 2 for Peptide 2
(note: the µl added of the peptide will vary to match µM). This procedure only differs from the
Zoom blot in having no washing or rinsing steps with blocking buffer and rinsing buffer. Protein
preparation and dilution remains the same for the stock concentration.
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Table 2: Sample Preparation for Western Blotting

------ --

-

.- �d

Tube 1
O,iM

Tube 2

-- 10 ,iM-

--

Tube 3

Tub�

Tube 5

I Tube 6

20 pM

30 ,iM

40 pM

50 pM

60 uM

I

3 µL

3 µL

3 µL

3 µL

3 ul

3 µL

3 µL

3 µL

3 uL

17.6 µL

22 µL

26.4 µL

Tube 7

concentration
Expressed DI

3 µL

3 µL

Expressed D2

3 µL

3 µL

Peptide 2:

O µL

4.4 µL

3 µL

3µL

EERRAQ
1 ° antibody for

Dl
PBS buffer

c�--:ol me
�

3 µL

I

8.9 µL r .2 µL -3

-

---

3µL

3µL

3µL

3µL

3µL

I

44 µL

39.6 µL

35.1 µL

30.8 µL

26.4 µL

22 µL

17.6 µL

-53 µL

53 µL

53 µL

53 µL

53 µL

53 µL

53 µL

After samples are prepared, they are incubated overnight in a cold room shaker at 4°C. 20 µl of
agarose beads are then added to 8 new cuvettes and washed twice with 300 µl PBS. Washes were
done by adding the amount of PBS, centrifuging the tubes for I minute at 4,000 rpm, and
discarding the supernatant. More PBS was then added to the next wash. The beads must be
washed in order to get remove any residuals and contamination off from the beads. The beads are
then added to each sample to pull down the DI-D2 complex by binding to the primary antibody.
The beads with the sample are then incubated in a cold room shaker at 4°C. The sample tubes
were then centrifuged at 4,000 rpm for one minute. 40 µl of supernatant was then drawn from
each tube and set aside in new sample cuvettes. The beads were then washed with 80 µl of PBS
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at 3,000 rpm, discarding the supernatant each time and adding more PBS after each wash. 10 µI
of supernatant in each was then discarded and IO µI of 5X SSB was added to each sample
cuvette containing the agarose beads as well as to the 40 µl cuvettes containing supernatant. All
the samples (beads and the supernatant) were then boiled for 10 minutes at 95°C. The samples
(beads and supernatant) were then loaded onto SOS-PAGE on 12% acrylamide gels with a 5%
stacking gel for I hour at l OOV. The protein ladder used was Benchmark™ from Invitrogen. The
Ix SOS-PAGE buffer for the tank was made with 200 ml of%x Tris/glicne buffer, 750ml of
ultrapure water, and 5 ml of 20% SOS. The recipes for the 12% acrylamide and 5% stacking gel
is shown below in Table 3.

Table 3: Recipes for 12% separating gel and 5% stacking gel

I

12% separating_gel 5% stacki ng_ge I
H20 (ml)
3.4
4.19
11.s M Tris, HCI pH 8.8 (ml)
2.5
0.75
Acrvl/Bis 40/1, 30 % (ml)
4
1
so
30
I sos 20% (µI)
IAPS 10% (µI)
100
TEMED (1!1)
10
6
Final Volume (ml
10.06
6.036
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Filter paper, sponge, and the nitrocellulose paper were soaked in Western Transfer Buffer. The
western transfer buffer was first cooled to about -10°C. The Western Transfer buffer was made
with 200 ml of lOx western buffer, 1400 ml of distilled water, and 400 ml ethanol. The gel was
then transferred to a sandwich of layers of sponge, filter paper, and nitrocellulose after running
SDS-PAGE. The gel is then covered by the nitrocellulose paper. The diagram of the sandwich is
shown in figure 7. Proteins in the transfer buffer are negative in charge and they therefore moved
from the -ve to +ve pole. So the +ve was above the nitrocellulose and the -ve side is below the
gel.

+
Sponge
Alter paper
- Membrane
- Gel
Filter paper
....................................... Sponge

J
J

t:

::)

-ve

Figure 7: Sandwich for the Western Transfer Buffer.
The tank containing the sandwich was then filled with Western Transfer buffer and the apparatus
was allowed to run for 1 hr and 30 min at 100 V. All air bubbles were removed from the
sandwich to allow complete transfer of the gel to the nitrocellulose paper. The Western Buffer
apparatus was covered with ice to prevent overheating.
After transfer, the nitrocellulose membranes were removed and placed face up in a
blotting box, allowing it to soak in the western transfer buffer for 30 minutes. The excess western
20

transfer buffer was then removed. Each nitrocellulose paper was then washed with 15ml of
TBST (Tris Buffered Saline Tween) for three times. TBST was made with 100 ml of TBS 1Ox,
900 ml distilled water, and 1ml Tween 20%. 5 ml of blocking buffer was then added to each
membrane. This was done by diluting 0.5 g of non-fat dry milk in 10 ml ofTBST. 2 µl of
primary DI antibody was added to the mix. This was then allowed to block overnight in a cold
room at 46C on a shaker. The blocking buffers were used to prevent non-specific binding. The
membranes were then washed with 15 ml TBST six times each for 5 minutes. Another blocking
buffer by adding 2 µI of secondary D2 antibody to 0.5 grams of milk in 10 ml TBST. 5ml was
added to each membrane. It was then allowed to incubate overnight in a cold room on a shaker.
The membranes were then washed with 15 ml ofTBST 6x for 5 minutes. The nitrocellulose
membranes were then transferred and imaged with 10µ1 of Clarity™ Western ECL mix was
added to each well. This was done by mixing 1 ml of peroxide solution and 1 ml of luminol
enhancer. 1ml was then added to each membrane and the membranes were allowed to develop
for 10 minutes. They were then imaged using BioRad™. A summary of the co
immunoprecipitation technique is shown below in Figure 8.
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Figure 9: Schematic summary of a standard co-immunoprecipitation
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Figure 9A: Co-immunoprecipitaion of 0.5 µg of DI and D2 receptors in the presence of
increasing concentration of peptides. The two proteins were incubated without and with varying
concentrations of peptides. DI was pulled down with DI specific antibodies, and the amount of
D2 bound to DI was detected by zoom blotting using D2 specific antibodies. Blots were
developed, quantitated using Image J (Materials and Methods). Processing of the data was
carried out with the GraphPad software using nonlinear regression and a dose response curve fit.
The graph summarizes the results expressed as means ± SE and normalized to control (P < 0.05,
n = 5).

Figure 9B: Upper panel represents an example of dot blotting using peptide 4 and lower panel
represents that using peptide 1. Concentrations from left to right are 0, 26, 37, 111, 185, 297,
and 408 µM of peptide.
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Starting from left to right on figure 8 ofthe co-immunoprecipitation dot blot, we have the
control, which ideally consists of only the Dl-D2 heteromer. It is the darkest dot and ideally, to
have an effective complex-uncoupling peptide, the intensity should decrease and get lighter as
the peptide concentration increases. As the concentration of peptide 1 increases, the relative
intensity of the dots tended to decrease.
In figure A, the same concentration of peptide I was added to each well, showing no
change in the relative intensity of the control. This figure served as a comparison for figure 8.
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Figure 10: Shows the decrease ofthe relative intensity of the control to peptide concentration.
Concentrations from left to right are 0, 26, 37, 1 1 1 , 185, 297, and 408 µM of peptide.
It can be shown in Figure 9 that Peptide 1 was the most effective, essentially uncoupling almost
all of the Dl-D2 heteromer at about 300 µM. Peptide 2 was minimally effective decreasing the
intensity of the control by about 20%. Peptide 3 and 4 had little to no effect in uncoupling the
heteromer.
These peptides have varying ICso values, which is the concentration of the peptide needed to
inhibit 50% of the Dl-D2 complex formation, or in this case, the concentration needed to
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decrease the relative intensity of 50% of the control. The respective ICso values can be found in
Table 4.
Table 4: Summary of each of the peptides ICSO values derived from Figure 10

Name

Sequence

IC50 Values (µM)

Peptide #1
Peptide #2

Ac-EAARRAQE

75.37

Ac-EERRAQ

> 350

Peptide #3
Peptide#4

Ac-ARRA

> 550

Ac-AARRAQ

> 550

We can see that Peptide 1 can inhibit 50% of the Dl-D2 complex formation at 75.37 µM while
peptides 2,3, and 4 needed much higher concentrations. To explore this further, we synthesized
a D-version of peptide 1 to test the effectiveness of changing the amino acid stereochemistry.
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Western Blotting Results
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Figure 11: Shows the decrease of the relative intensity of the control to increasing peptide
concentration. Western blot ofOl coimrnunoprecipitated in the presence of increasing
concentrations of peptide 1 and 0-peptide 1 and visualized using 02 antibodies. Lanes 1-8
correspond to 0, 25, 50, 75, 100, 125, 150, and 175 µM, respectively. Concentrations from left to
right are 0, 26, 37, 111, 185, 297, and 408 µM of peptide 1 and 0-peptide 1.

It can be seen that the 0-peptide 1 is even more effective than the L-peptide in disrupting the 0102 heteromer. This can also be seen observing the ICso values.
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Table 5: Shows the ICSO values for the O and L-peptide I

Name
Pe tide #1
D-Pe tide #l

Sequence

IC50 Values (µM)
75.37
42.11

D-peptide I needed almost only half the concentration of the L-peptide I to be 5 0% effective
against the 01-D2 heteromer.
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Figure 12: Western blot of Ol coimmunoprecipitated with 02 in the absence (A) and presence
(B) of increasing concentrations of D-peptide I and visualized using 02 antibodies. Lanes 1-8
correspond to 0, 25, SO, 75, 100, 125, 150, and 175 µM, respectively.

In Figure 128, lane 2 seems to be an outlier, as the intensity of the dot is higher with a greater
concentration of Peptide 1 added. Otherwise, a clear trend is observed where increasing peptide
resulted in receptor uncoupling.
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Discussion
The four different peptides were synthesized according to the interface identified between
the intracellular loop ofD2 and the carboxy tail of DI as indicated by O 'Dowd et. Al. 2012. This
area consists of charged amino acid residues such as glutamate, aspartate, arginine, and lysine.
From our results, we can conclude that both the L- and D-Peptide I Ac-EAARRAQE prove to be
the best inhibitors of the Dl-D2 heteromer complex. Interestingly enough, this may indicate that
the D-form of other small peptides may be more effective in inhibiting the formation of the
heteromer. Peptide I only differs from Peptide 4 by two glutamates at the ends, yet much is more
effective as indicated by their ICso (75.37 µM Peptide I and >350 µM Peptide 4). This may
indicate that the crucial interface maintaining theDI and D2 may be larger than expected
between the carboxy tail of DI and the intracellular loop ofD2.

Conclusion
DI and D2 can be uncoupled by a small peptide as confirmed by other studies (I), but it
is not certain if our selected peptides bind between the carboxyl tail ofDI and intracellular loop
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3 of 02. There may be other interfaces maintaining the stability of the heteromer. Also our
peptides were only shown to bind to 01, to uncouple the heteromer. In the future we may
examine other intracellular loops of 02, possibly creating a peptide that may be even more
effective in uncoupling 01-02.
Future Directions

We plan to observe the effects of the D-stereoisomer of the other three peptides on the ICso
values. 0-peptides may be more effective in heteromer uncoupling. We also plan to test our
peptides on HeLa cells in vivo, cells that express DI and D2 endogenously, as well as observe the
effects of our peptides on PC12 cells (pheochromocytoma). Developing a peptide that may
uncouple the heteromer can possibly serve to alieve the symptoms of depression and act as a
possible medical intervention.
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